Join
Live feed
·
INSIDERFilingvia Quantisnow
Lineage Cell Therapeutics Inc. logo

Director Mulroy Michael H. bought $22,640 worth of shares (40,000 units at $0.57), increasing direct ownership by 15% to 298,555 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
LCTX· Lineage Cell Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LCTX (Lineage Cell Therapeutics Inc.) and more on Quantisnow.